NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages

Ronald C. Petersen, Heather J. Wiste, Stephen D. Weigand, Julie A. Fields, Yonas E. Geda, Jonathan Graff-Radford, David S. Knopman, Walter K. Kremers, Val Lowe, Mary M. Machulda, Michelle M. Mielke, Nikki H. Stricker, Terry M. Therneau, Prashanthi Vemuri, Clifford R. Jack

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: To operationalize the National Institute on Aging – Alzheimer's Association (NIA-AA) Research Framework for Alzheimer's Disease 6-stage continuum of clinical progression for persons with abnormal amyloid. Methods: The Mayo Clinic Study of Aging is a population-based longitudinal study of aging and cognitive impairment in Olmsted County, Minnesota. We evaluated persons without dementia having 3 consecutive clinical visits. Measures for cross-sectional categories included objective cognitive impairment (OBJ) and function (FXN). Measures for change included subjective cognitive impairment (SCD), objective cognitive change (ΔOBJ), and new onset of neurobehavioral symptoms (ΔNBS). We calculated frequencies of the stages using different cutoff points and assessed stability of the stages over 15 months. Results: Among 243 abnormal amyloid participants, the frequencies of the stages varied with age: 66 to 90% were classified as stage 1 at age 50 but at age 80, 24 to 36% were stage 1, 32 to 47% were stage 2, 18 to 27% were stage 3, 1 to 3% were stage 4 to 6, and 3 to 9% were indeterminate. Most stage 2 participants were classified as stage 2 because of abnormal ΔOBJ only (44–59%), whereas 11 to 21% had SCD only, and 9 to 13% had ΔNBS only. Short-term stability varied by stage and OBJ cutoff points but the most notable changes were seen in stage 2 with 38 to 63% remaining stable, 4 to 13% worsening, and 24 to 41% improving (moving to stage 1). Interpretation: The frequency of the stages varied by age and the precise membership fluctuated by the parameters used to define the stages. The staging framework may require revisions before it can be adopted for clinical trials. ANN NEUROL 2021;89:1145–1156.

Original languageEnglish (US)
Pages (from-to)1145-1156
Number of pages12
JournalAnnals of Neurology
Volume89
Issue number6
DOIs
StatePublished - Jun 2021
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages'. Together they form a unique fingerprint.

Cite this